SCHEMBL2124746

SCHEMBL2124746

Cc1ccc(Nc2c(-c3ccccc3)nc3c(C#N)c[nH]n23)c(C)c1

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 14/20 0.52
▸ KDM6B O15054 1/20 0.51
▸ KDM5C P41229 1/20 0.51
▸ KDM5D Q9BY66 1/20 0.51
▸ KDM4C Q9H3R0 1/20 0.51
▸ KDM5B Q9UGL1 1/20 0.51
▸ PHF8 Q9UPP1 1/20 0.51
▸ MAPT P10636 4/20 0.50
▸ TP53 P04637 2/20 0.50
▸ GAA P10253 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2124502 0.91 KDM5A (0.53) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2122447 0.90 KDM5A (0.53) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2873329 0.89 KDM5A (0.56) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2123625 0.88 KDM5A (0.48) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2125875 0.88 KDM5A (0.47) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2124763 0.88 KDM5A (0.47) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2123179 0.86 KDM5A (0.58) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2125909 0.86 GAA (0.49) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2124113 0.86 KDM5A (0.46) KDM5AKDM6BKDM5CKDM5DKDM4C
SCHEMBL2124375 0.86 MAPT (0.45) KDM5AMAPTTP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK KDM5A 1592/4885KDM6B 958/4885KDM5C 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback